uniQure Faces Securities Fraud Class Action Lawsuit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy QURE?
Source: Globenewswire
- Class Action Notice: Bernstein Liebhard LLP reminds investors that uniQure N.V. is facing a securities fraud class action lawsuit involving investors who purchased shares between September 24, 2025, and October 31, 2025, alleging violations of the Securities Exchange Act of 1934 against the Company and its senior officers.
- Lawsuit Details: The lawsuit was filed in the U.S. District Court for the Southern District of New York, claiming that the defendants made misrepresentations regarding AMT-130, a drug being developed for Huntington’s Disease, potentially leading to investor losses.
- Investor Action Guidance: Investors wishing to participate in the lawsuit or serve as lead plaintiff must file papers by April 13, 2026; those who take no action will remain absent class members and may miss out on any potential recovery.
- Legal Fee Arrangement: All representation is on a contingency fee basis, meaning shareholders pay no fees or expenses, which lowers the financial burden on investors and encourages more affected shareholders to take action.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QURE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QURE
Wall Street analysts forecast QURE stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 17.115
Low
33.00
Averages
49.88
High
70.00
Current: 17.115
Low
33.00
Averages
49.88
High
70.00
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
uniQure to Announce Q4 Earnings on March 2
- Earnings Announcement: uniQure is set to release its Q4 2023 earnings results on March 2 before the market opens, with investors keenly awaiting insights into its financial performance and future outlook.
- Earnings Expectations: The consensus EPS estimate stands at -$0.93, indicating challenges in profitability that could potentially affect investor confidence and stock performance.
- Revenue Estimate Changes: Over the past three months, revenue estimates have seen one upward revision and four downward revisions, with the current estimate at $5.56 million, reflecting a cautious market sentiment regarding uniQure's future revenue growth.
- Analyst Rating Dynamics: Despite four upward revisions and no downward adjustments in EPS estimates over the last three months, the overall downward trend in revenue expectations may dampen market sentiment towards uniQure's stock performance.
See More
uniQure Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: uniQure N.V. (NASDAQ:QURE) is facing a securities fraud class action lawsuit for material misstatements regarding its Huntington's disease gene therapy drug during the period from September 24 to October 31, 2025, with investors able to apply for lead plaintiff status by April 13, 2026.
- Stock Price Plunge: Following the revelation on November 3, 2025, that the FDA no longer accepted the clinical trial data for AMT-130, uniQure's stock price plummeted by $33.40, or over 49%, from $67.69 on October 31 to $34.29, reflecting significant market concerns about the company's future prospects.
- Legal Action: Investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for a no-cost legal consultation, indicating that the company's potential liability in the securities fraud case may provide recovery opportunities for affected investors.
- Uncertain Company Outlook: uniQure admitted that the timeline for its Biologics License Application (BLA) submission is now unclear, despite plans to urgently interact with the FDA, which may further undermine investor confidence and the company's future financing capabilities.
See More
Notice of Class Action Lawsuit for uniQure Shareholders
- Class Action Notice: Rosen Law Firm reminds investors who purchased ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025, and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that defendants failed to adequately disclose design flaws in the pivotal study of uniQure's leading drug candidate, which was not fully approved by the FDA, resulting in investor losses when the true information was revealed, thereby impacting the company's market credibility.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its successful track record and resources, urging investors to select qualified counsel with proven success in leadership roles.
- Investor Action Recommendation: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, with the opportunity to join the class action without any upfront fees, ensuring proper representation in the legal process.
See More
Class Action Lawsuit Announced for uniQure N.V.
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of uniQure N.V. ordinary shares between September 24, 2025, and October 31, 2025, indicating potential investor losses due to misrepresentation.
- Compensation Structure: Investors participating in the lawsuit may receive compensation without any out-of-pocket costs, which reduces financial burdens and encourages more affected parties to join the action.
- Counsel Selection Importance: The firm emphasizes the necessity of choosing qualified legal counsel with a successful track record to ensure effective representation in litigation, thereby avoiding inexperienced intermediaries.
- Disclosure of Case Details: The lawsuit alleges that uniQure failed to fully disclose that its pivotal study design was not fully approved by the FDA, leading to investor losses when the true information was revealed, highlighting potential issues in the company's transparency and compliance.
See More
FDA Raises Concerns Over Invasive Gene Therapies
- Regulatory Pressure Intensifies: FDA Commissioner Marty Makary's concerns over invasive gene therapies led to a 31% drop in UniQure's AMT-130 stock, hitting a five-month low, indicating investor panic over regulatory prospects that could impact the company's funding and R&D efforts.
- Divergent Analyst Opinions: While RBC Capital Markets views Makary's comments as directed at UniQure, Leerink suggests they may refer to Regenxbio's RGX-121, reflecting market uncertainty regarding FDA regulatory policies that could erode investor confidence.
- Clinical Trial Challenges: Regenxbio's RGX-121 recently faced a Complete Response Letter from the FDA, citing uncertainties around study population definitions and surrogate endpoints, further heightening market concerns about its future development and competitive position.
- Opportunities in Personalized Therapies: Despite challenges, the FDA's recent draft guidance offers potential accelerated approvals for highly personalized gene therapies, indicating regulatory flexibility in treating ultra-rare conditions, which may present new growth opportunities for related companies.
See More
Class Action Notice for uniQure N.V. Shareholders
- Class Action Deadline: Rosen Law Firm reminds investors who purchased uniQure N.V. shares between September 24 and October 31, 2025, that they must apply to be lead plaintiffs by April 13, 2026, to protect their rights in the class action lawsuit.
- Lawsuit Background: The lawsuit alleges that uniQure failed to adequately disclose that its pivotal study design for a leading drug candidate was not fully approved by the FDA, resulting in investor losses when the true information became public, highlighting significant transparency and compliance issues within the company.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating a strong track record and extensive experience, which investors should consider when selecting legal counsel to ensure professional support.
- Investor Action Steps: Investors can visit the Rosen Law Firm website or call the toll-free number for more information on how to participate in the lawsuit, ensuring they receive appropriate legal representation in the class action and avoid being ineffective absent members.
See More
uniQure to Announce Q4 Earnings on March 2
- Earnings Announcement: uniQure is set to release its Q4 2023 earnings results on March 2 before the market opens, with investors keenly awaiting insights into its financial performance and future outlook.
- Earnings Expectations: The consensus EPS estimate stands at -$0.93, indicating challenges in profitability that could potentially affect investor confidence and stock performance.
- Revenue Estimate Changes: Over the past three months, revenue estimates have seen one upward revision and four downward revisions, with the current estimate at $5.56 million, reflecting a cautious market sentiment regarding uniQure's future revenue growth.
- Analyst Rating Dynamics: Despite four upward revisions and no downward adjustments in EPS estimates over the last three months, the overall downward trend in revenue expectations may dampen market sentiment towards uniQure's stock performance.
See More
uniQure Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: uniQure N.V. (NASDAQ:QURE) is facing a securities fraud class action lawsuit for material misstatements regarding its Huntington's disease gene therapy drug during the period from September 24 to October 31, 2025, with investors able to apply for lead plaintiff status by April 13, 2026.
- Stock Price Plunge: Following the revelation on November 3, 2025, that the FDA no longer accepted the clinical trial data for AMT-130, uniQure's stock price plummeted by $33.40, or over 49%, from $67.69 on October 31 to $34.29, reflecting significant market concerns about the company's future prospects.
- Legal Action: Investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for a no-cost legal consultation, indicating that the company's potential liability in the securities fraud case may provide recovery opportunities for affected investors.
- Uncertain Company Outlook: uniQure admitted that the timeline for its Biologics License Application (BLA) submission is now unclear, despite plans to urgently interact with the FDA, which may further undermine investor confidence and the company's future financing capabilities.
See More
Notice of Class Action Lawsuit for uniQure Shareholders
- Class Action Notice: Rosen Law Firm reminds investors who purchased ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025, and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that defendants failed to adequately disclose design flaws in the pivotal study of uniQure's leading drug candidate, which was not fully approved by the FDA, resulting in investor losses when the true information was revealed, thereby impacting the company's market credibility.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its successful track record and resources, urging investors to select qualified counsel with proven success in leadership roles.
- Investor Action Recommendation: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, with the opportunity to join the class action without any upfront fees, ensuring proper representation in the legal process.
See More
Class Action Lawsuit Announced for uniQure N.V.
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of uniQure N.V. ordinary shares between September 24, 2025, and October 31, 2025, indicating potential investor losses due to misrepresentation.
- Compensation Structure: Investors participating in the lawsuit may receive compensation without any out-of-pocket costs, which reduces financial burdens and encourages more affected parties to join the action.
- Counsel Selection Importance: The firm emphasizes the necessity of choosing qualified legal counsel with a successful track record to ensure effective representation in litigation, thereby avoiding inexperienced intermediaries.
- Disclosure of Case Details: The lawsuit alleges that uniQure failed to fully disclose that its pivotal study design was not fully approved by the FDA, leading to investor losses when the true information was revealed, highlighting potential issues in the company's transparency and compliance.
See More
FDA Raises Concerns Over Invasive Gene Therapies
- Regulatory Pressure Intensifies: FDA Commissioner Marty Makary's concerns over invasive gene therapies led to a 31% drop in UniQure's AMT-130 stock, hitting a five-month low, indicating investor panic over regulatory prospects that could impact the company's funding and R&D efforts.
- Divergent Analyst Opinions: While RBC Capital Markets views Makary's comments as directed at UniQure, Leerink suggests they may refer to Regenxbio's RGX-121, reflecting market uncertainty regarding FDA regulatory policies that could erode investor confidence.
- Clinical Trial Challenges: Regenxbio's RGX-121 recently faced a Complete Response Letter from the FDA, citing uncertainties around study population definitions and surrogate endpoints, further heightening market concerns about its future development and competitive position.
- Opportunities in Personalized Therapies: Despite challenges, the FDA's recent draft guidance offers potential accelerated approvals for highly personalized gene therapies, indicating regulatory flexibility in treating ultra-rare conditions, which may present new growth opportunities for related companies.
See More
Class Action Notice for uniQure N.V. Shareholders
- Class Action Deadline: Rosen Law Firm reminds investors who purchased uniQure N.V. shares between September 24 and October 31, 2025, that they must apply to be lead plaintiffs by April 13, 2026, to protect their rights in the class action lawsuit.
- Lawsuit Background: The lawsuit alleges that uniQure failed to adequately disclose that its pivotal study design for a leading drug candidate was not fully approved by the FDA, resulting in investor losses when the true information became public, highlighting significant transparency and compliance issues within the company.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating a strong track record and extensive experience, which investors should consider when selecting legal counsel to ensure professional support.
- Investor Action Steps: Investors can visit the Rosen Law Firm website or call the toll-free number for more information on how to participate in the lawsuit, ensuring they receive appropriate legal representation in the class action and avoid being ineffective absent members.
See More
